Schnitzer Announces First Quarter Fiscal 2021 Earnings Date and Conference Call Webcast Details

Schnitzer Announces First Quarter Fiscal 2021 Earnings Date and Conference Call Webcast Details

PORTLAND, Ore.–(BUSINESS WIRE)–
Schnitzer Steel Industries, Inc. (NASDAQ: SCHN) today announced that the Company will report financial results for its first quarter fiscal 2021 ended November 30, 2020 on Thursday, January 7, 2021 and will host a webcast conference call to discuss the results at 11:30 a.m. Eastern Time on the same day. The webcast of the call and the accompanying slide presentation may be accessed on Schnitzer’s website under Company > Investors > Event Calendar at www.schnitzersteel.com/events. The call will be hosted by Tamara Lundgren, Chairman and Chief Executive Officer, and Richard Peach, Executive Vice President, Chief Financial Officer and Chief Strategy Officer.

Replay Information

Toll Free Dial: (855) 859-2056

Toll Free International Dial: (404) 537-3406

Conference ID: 7294302

Replay Available: 01/07/2021 to 01/12/2021

About Schnitzer Steel Industries, Inc.

Schnitzer Steel Industries, Inc. is one of the largest manufacturers and exporters of recycled metal products in North America with operating facilities located in 23 states, Puerto Rico and Western Canada. Schnitzer has seven deep water export facilities located on both the East and West Coasts and in Hawaii and Puerto Rico. The Company’s integrated operating platform also includes 50 stores which sell serviceable used auto parts from salvaged vehicles and receive approximately 5 million annual retail visits. The Company’s steel manufacturing operations produce finished steel products, including rebar, wire rod and other specialty products. The Company began operations in 1906 in Portland, Oregon.

Investor Relations: Michael Bennett (503) 323-2811

Website: www.schnitzersteel.com

Email: [email protected]

KEYWORDS: Oregon United States North America

INDUSTRY KEYWORDS: Steel Manufacturing

MEDIA:

Logo
Logo

Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

Leading CDMO seamlessly managing quality processes and content for greater visibility and compliance across global manufacturing

SEOUL, South Korea–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) today announced that Samsung Biologics, an award-winning global contract development and manufacturing organization (CDMO), has adopted Veeva Vault QMS to streamline quality management on a single cloud platform. The addition of Vault QMS builds upon the company’s success with Veeva Vault QualityDocs for more efficient document control and management. Together as part of the Veeva Vault Quality Suite, Samsung Biologics is bringing together quality process and content management for improved visibility across their global processes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005611/en/

“Veeva enables us to unify quality management for greater end-to-end control of quality manufacturing around the world,” said James Choi, senior vice president and CIO of Samsung Biologics. “With a modern technology foundation, we can deliver value-added services that help our customers stay ahead of changing business and regulatory requirements.”

Samsung Biologics provides development, manufacturing, and laboratory testing services across the product lifecycle. The CDMO required a scalable system that would provide internal and external stakeholders with transparency into enterprise quality and document management processes.

Vault QMS is a modern cloud application that unifies quality management and easily incorporates Samsung Biologics’ internal organization, pharmaceutical and biotech customers, contract manufacturers, and suppliers into one quality process. This allows Samsung Biologics to better align its global processes for greater visibility and compliance throughout the product lifecycle.

“Samsung Biologics is an innovative company that is leading the way in modernizing quality manufacturing,” said Chris Shim, Veeva vice president R&D Asia. “We’re excited to expand our partnership with Samsung Biologics and support their strategy to harmonize quality processes and meet the evolving needs of the global healthcare industry.”

To learn more about Veeva Vault Quality Suite, register to access exclusive content from the 2020 Veeva R&D and Quality Summit. The on-demand sessions feature case studies in quality and manufacturing and are only open to life sciences professionals.

Additional Information

For more on Veeva Vault QMS, visit: veeva.com/QMS

Connect with Veeva APAC on LinkedIn: linkedin.com/company/veeva-systems-apac

Follow @veevasystems on Twitter: twitter.com/veevasystems

Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 950 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.

About Samsung Biologics

Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services. With proven regulatory approvals, the largest capacity at a single site, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide. For more information, visit www.samsungbiologics.com.

Veeva Systems Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

Samsung Biologics Forward-looking Statements

This press release contains certain statements that constitute forward-looking statements, including statements that describe Samsung Biologics’ objectives, plans or goals. All such forward-looking statements, and the assumptions on which they are based, are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. There can be no assurance that the results and events contemplated by the forward-looking statements contained herein will in fact occur. Except as required by law, Samsung Biologics will not update any forward-looking statements to reflect material developments that may occur after the date of this press release.

Brittagh Lynn

Veeva Systems APAC

+61435922069

[email protected]

Bec Sands

Polkadot Communications

+61416119858

[email protected]

Claire Kim

Samsung Biologics

[email protected]

KEYWORDS: Asia Pacific South Korea

INDUSTRY KEYWORDS: Software Biotechnology Networks Pharmaceutical Internet Health Data Management Technology

MEDIA:

Logo
Logo
Logo
Logo

Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

Leading CDMO seamlessly managing quality processes and content for greater visibility and compliance across global manufacturing

PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) today announced that Samsung Biologics, an award-winning global contract development and manufacturing organization (CDMO), has adopted Veeva Vault QMS to streamline quality management on a single cloud platform. The addition of Vault QMS builds upon the company’s success with Veeva Vault QualityDocs for more efficient document control and management. Together as part of the Veeva Vault Quality Suite, Samsung Biologics is bringing together quality process and content management for improved visibility across their global processes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005610/en/

“Veeva enables us to unify quality management for greater end-to-end control of quality manufacturing around the world,” said James Choi, senior vice president and CIO of Samsung Biologics. “With a modern technology foundation, we can deliver value-added services that help our customers stay ahead of changing business and regulatory requirements.”

Samsung Biologics provides development, manufacturing, and laboratory testing services across the product lifecycle. The CDMO required a scalable system that would provide internal and external stakeholders with transparency into enterprise quality and document management processes.

Vault QMS is a modern cloud application that unifies quality management and easily incorporates Samsung Biologics’ internal organization, pharmaceutical and biotech customers, contract manufacturers, and suppliers into one quality process. This allows Samsung Biologics to better align its global processes for greater visibility and compliance throughout the product lifecycle.

“Samsung Biologics is an innovative company that is leading the way in modernizing quality manufacturing,” said Chris Shim, Veeva vice president R&D Asia. “We’re excited to expand our partnership with Samsung Biologics and support their strategy to harmonize quality processes and meet the evolving needs of the global healthcare industry.”

To learn more about Veeva Vault Quality Suite, register to access exclusive content from the 2020 Veeva R&D and Quality Summit. The on-demand sessions feature case studies in quality and manufacturing and are only open to life sciences professionals.

Additional Information

For more on Veeva Vault QMS, visit: veeva.com/QMS

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

Follow @veevasystems on Twitter: twitter.com/veevasystems

Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 950 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.

About Samsung Biologics

Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services. With proven regulatory approvals, the largest capacity at a single site, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide. For more information, visit www.samsungbiologics.com.

Veeva Systems Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

Samsung Biologics Forward-looking Statements

This press release contains certain statements that constitute forward-looking statements, including statements that describe Samsung Biologics’ objectives, plans or goals. All such forward-looking statements, and the assumptions on which they are based, are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. There can be no assurance that the results and events contemplated by the forward-looking statements contained herein will in fact occur. Except as required by law, Samsung Biologics will not update any forward-looking statements to reflect material developments that may occur after the date of this press release.

Roger Villareal

Veeva Systems

925 264 8885

[email protected]

Deivis Mercado

Veeva Systems

925 226 8821

[email protected]

Claire Kim

Samsung Biologics

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Technology Manufacturing Software Networks Other Manufacturing Internet

MEDIA:

Logo
Logo
Logo
Logo

Nortech Systems Announces Two New Board Members

 Nortech Systems Announces Two New Board Members

MINNEAPOLIS–(BUSINESS WIRE)–Nortech Systems Incorporated (Nasdaq: NSYS), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical, aerospace & defense and industrial markets, announced today Phil Smith and Dan Sachs were recently appointed to the company’s board of directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005825/en/

Dan Sachs (Photo: Business Wire)

Dan Sachs (Photo: Business Wire)

“We are happy to welcome Mr. Smith and Dr. Sachs to our board of directors,” said Jay Miller, Nortech’s Systems’ president and CEO. “In recent years, Nortech’s strategic investments in the U.S., Mexico and China, coupled with important measures taken to strengthen its balance sheet, have diversified the company’s capabilities and improved efficiencies to enhance profitability and support future growth.” Miller added, “Phil and Dan bring a wealth of management and financial expertise to help guide and oversee that future growth and profitability.”

Mr. Smith’s 25 years of healthcare experience includes investment banking as well as executive management. Mr. Smith currently serves as a Managing Director of the Healthcare M&A practice at Duff & Phelps, an investment banking firm that provides valuation, corporate finance and other services. He has expertise in assisting public and private companies as well as private equity firms. Prior to Duff & Phelps, he held positions at BMO Capital Markets (formerly Greene, Holcomb and Fisher), where he focused on healthcare mergers and acquisitions. Before that, he was a member of the medical device investment banking team at Piper Jaffray in Minneapolis. Earlier in his career, Smith served as an executive for DIGIMED Ortho, Vital Images, Thermonix and Image-Guided Neurologics. Smith began his career as a successful sales leader at GE Medical Systems (now GE Healthcare). Smith received an MBA from the Wharton School of the University of Pennsylvania and a B.S. in electrical engineering from the University of Florida.

Dr. Sachs brings broad experience as a medical professional, investor, and entrepreneur with a keen focus on medical device technology and startups. Dr. Sachs is a founder of Respicardia, Inc. (FKA Cardiac Concepts), and Mainstay Medical Inc., and Program Director of the Innovation Fellows Program within the Institute for Engineering in Medicine at the University of Minnesota. He was previously a venture capital investor with Investor Growth Capital and Spray Venture Partners, for which he was the founding investor in CoTherix, Inc. (CTRX, FKA Exhale Therapeutics), Neuronetics, Inc. (STIM), and other private companies. He served on the Board of Directors of Neuronetics, Inc., CoTherix, Inc. (acquired), CHF Solutions Inc. (acquired), Respicardia, Inc, and Mainstay Medical, Inc. He previously served as Instructor in Medicine in the Division of Emergency Medicine at Harvard Medical School. Dr. Sachs earned BA and MD degrees from the University of Michigan, and an MBA from Harvard Business School.

Nortech specializes in complex cable harnesses, printed circuit board assemblies (PCBAs) and box builds for low-volume, high-mix global engineering development and manufacturing. Nortech’s 30-year history and rapidly growing expertise in digital connectivity and data management helps its customers stay competitive today and well into the future.

Nortech uses intelligence, innovation, speed, and global expertise to provide high-quality, high performance engineering and manufacturing solutions to resolve our customers’ most important challenges to be leaders in secure, reliable digital connectivity & data management. Nortech strives to be a premier workplace that fosters valued relationships internally and in our communities.

About Nortech Systems Incorporated Nortech Systems is a leading provider of design and manufacturing solutions for complex electromedical devices, electromechanical systems, assemblies, and components. Nortech Systems primarily serves the medical, aerospace & defense, and industrial markets. Its design services span concept development to commercial design, and include medical device, software, electrical, mechanical, and biomedical engineering. Its manufacturing and supply chain capabilities are vertically integrated around wire/cable/interconnect assemblies, printed circuit board assemblies, as well as system-level assembly, integration, and final test. Headquartered in Maple Grove, Minn., Nortech currently has seven manufacturing locations and design centers across the U.S., Latin America, and Asia. Nortech Systems is traded on the NASDAQ Stock Market under the symbol NSYS. Nortech’s website is www.nortechsys.com.

Jay Miller, President and CEO

(612) 720-2829

KEYWORDS: Minnesota United States North America

INDUSTRY KEYWORDS: Other Manufacturing Technology Medical Devices Engineering Aerospace Manufacturing Hardware Health Data Management

MEDIA:

Logo
Logo
Photo
Photo
Dan Sachs (Photo: Business Wire)
Photo
Photo
Philip Smith (Photo: Business Wire)

Canacol Energy Ltd. Announces Dividend

CALGARY, Alberta, Dec. 14, 2020 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX:CNE) (OTCQX:CNNEF) (BVC:CNEC) announced that it has declared a dividend of CAD$.052 per share, payable on January 15, 2021, to shareholders of record at the close of business on December 31, 2020. The ex-dividend date for all shareholders is December 30, 2020. This dividend qualifies as an ‘eligible dividend’ for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.

Dividends on shares traded on the Toronto Stock Exchange (“TSX”) will be paid in Canadian Dollars (“CAD”) on January 15, 2021.

For shareholders trading on the Colombia Stock Exchange (“BVC”), the Colombian peso equivalency shall be calculated based on the exchange rate as certified by the Banco de la Republica (“Central Bank”) on the date of monetization and will be published accordingly on the SIMEV website www.superfinanciera.gov.co

Shares traded on the Toronto Stock Exchange

Form NR301 will be mailed to Registered non-resident shareholders as at the dividend record date, by Olympia Trust Company, Canacol’s transfer agent. In order to receive the preferred treaty rate, you must complete and mail back the form as soon as possible. Failure to supply a completed NR301 form will result in Olympia withholding the statutory 25% withholding tax rate on any payments to Registered non-resident shareholders. If you have previously completed Form NR301, you do not need to complete a new form.

Instructions on how to correctly complete the NR301 are on the back of the form. Shareholders who hold their shares through a broker should contact their broker directly. They do not need to return a form to Olympia.

Shares traded on the Colombia Stock Exchange

Dividend payments will be subject to withholding at the Canadian statutory rate of 25%. Shareholders who are entitled to a reduced withholding tax rate under a tax treaty should contact their broker or nominee to submit Form NR301 (English version). Brokers should submit Form NR301 on behalf of their shareholders to Deposito Centralizado de Valores (“Deceval”) as soon as possible. If you have previously completed Form NR301, you do not need to complete a new form.

Form NR301 can be downloaded at:
https://www.canada.ca/content/dam/cra-arc/formspubs/pbg/nr301/nr301-13e.pdf

For information purposes, a Spanish version of Form NR301 can be downloaded at:
http://canacolenergy.co/investors/stocks-dividends/dividend-forms/

The content contained herein is not tax advice. Do not use or otherwise rely upon any of the content without first seeking independent tax advice.

About Canacol

Canacol Energy is a gas exploration and production company with operations focused in Colombia. The Corporation’s common stock trades on the Toronto Stock Exchange, the OTCQX in the United States of America, and the Colombia Stock Exchange under ticker symbol CNE, CNNEF, and CNE.C, respectively.

This press release contains certain forward-looking statements within the meaning of applicable securities law. Forward-looking statements are frequently characterized by words such as “plan”, “expect”, “project”, “target”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur, including without limitation statements relating to estimated production rates from the Corporation’s properties and intended work programs and associated timelines. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation cannot assure that actual results will be consistent with these forward looking statements. They are made as of the date hereof and are subject to change and the Corporation assumes no obligation to revise or update them to reflect new circumstances, except as required by law. Information and guidance provided herein supersedes and replaces any forward looking information provided in prior disclosures. Prospective investors should not place undue reliance on forward looking statements. These factors include the inherent risks involved in the exploration for and development of crude oil and natural gas properties, the uncertainties involved in interpreting drilling results and other geological and geophysical data, fluctuating energy prices, the possibility of cost overruns or unanticipated costs or delays and other uncertainties associated with the oil and gas industry. Other risk factors could include risks associated with negotiating with foreign governments as well as country risk associated with conducting international activities, and other factors, many of which are beyond the control of the Corporation.



For further information please contact:        

Investor Relations

South America: +571.621.1747 [email protected]

Global: +1.403.561.1648 [email protected]         

http://www.canacolenergy.com

UAES and ROHM Hold Opening Ceremony for a Joint Laboratory on SiC Technology

Kyoto, Japan and Santa Clara, CA, Dec. 14, 2020 (GLOBE NEWSWIRE) — ROHM, together with Chinese Tier 1 comprehensive automotive manufacturer United Automotive Electronic Systems Co., Ltd. (UAES), recently held an opening ceremony announcing the establishment of a joint laboratory on SiC technology at UAES headquarters in Shanghai, China.

SiC power devices are being increasingly adopted in the fields of electric vehicles, infrastructure, environment / energy, and industrial equipment. This is due, in large part, to the advantages they provide over silicon-based power devices such as IGBTs, including significantly reduced loss during both switching and conduction, along with support for higher temperature operation.

Since 2015, UAES and ROHM have been collaborating and carrying out detailed technical exchanges on automotive applications utilizing SiC power devices. After several years of technical exchanges, automotive products incorporating ROHM SiC power devices were released earlier this year.

The new joint laboratory contains important equipment required for device and application evaluation in automotive, such as onboard chargers and DC/DC converters. This will allow ROHM and UAES to strengthen their partnership and accelerate development of innovative power solutions centered on SiC.

Mr. Guo Xiaolu, Deputy General Manager, United Automotive Electronic Systems Co., Ltd., “With ROHM, which has been introducing SiC power devices since 2015, we have strengthened our collaboration, including top management. And after many years of technical exchanges, we are pleased to announce the successful development and mass production of SiC-equipped automotive applications this year. The establishment of this joint laboratory is a testament to the deepening relationship between our two companies, and we can look forward to further technical support through this new comprehensive facility.”

Dr. Kazuhide Ino, CSO and Senior Director of Power Device Business, ROHM Co., Ltd., “We are pleased to have established a joint laboratory with UAES, a leading manufacturer of automotive applications. As a leading supplier of SiC power devices, ROHM develops industry-leading devices and has a proven track record of providing power solutions that combine peripheral components such as driver ICs. In the rapidly expanding automotive sector, as research tailored to customer needs and market trends becomes an important factor, we will continue to strengthen our partnership through this joint research lab and contribute to technical innovation in the automotive sector with power solutions centered on SiC.”

About UAES (United Automotive Electronic Systems Co., Ltd.)

UAES, a comprehensive automotive Tier 1 manufacturer, was established as a joint venture by Robert Bosch and Zhonglian Automobile Electronics Systems Co., Ltd. (a Chinese company affiliated with SAIC). Founded in 1995, it has since gained a large share in the Chinese market for engine control units and powertrain systems for gas-powered vehicles, and from 2009 has focused on developing applications for electric vehicles, including the main inverters. For more information, please visit UAES’ official website: www.uaes.com

About ROHM

ROHM, a leading semiconductor and electronic component manufacturer, was established in 1958. From the automotive and industrial equipment markets to the consumer and communication sectors, ROHM supplies ICs, discretes, and electronic components featuring superior quality and reliability through a global sales and development network. Our strengths in the analog and power markets allow us to propose optimized solutions for entire systems that combine peripheral components (i.e., transistors, diodes, resistors) with the latest SiC power devices, as well as driver ICs that maximize their performance. Please visit ROHM’s website for more information: www.rohm.com

Terminology

IGBT (Insulated Gate Bipolar Transistor)

A power transistor that combines the high-speed switching characteristics of a MOSFET with the low conduction loss of a bipolar transistor.

Conduction and Switching Losses

Losses inevitably occur in transistors such as MOSFETs and IGBTs due to their particular device structure. Conduction loss is generated by the internal resistance component when current flows (ON state) through the device. Switching loss occurs when the conduction state of the device is switched (during switching operation).

Attachment



Travis Moench
ROHM Semiconductor
858.625.3600
[email protected]

Heather Savage
BWW Communications
720.295.0260
[email protected]

Primoris Services Corporation to Acquire Future Infrastructure Holdings, LLC to Establish Leading Platform in Telecommunication Services

DALLAS, Dec. 14, 2020 (GLOBE NEWSWIRE) — Primoris Services Corporation (NASDAQ Global Select: PRIM), (“Primoris” or the “Company”), a leading provider of specialty contracting services in North America, today announced that it has entered into a definitive merger agreement to acquire Future Infrastructure Holdings, LLC (“Future Infrastructure” or “FIH”) from Tower Arch Capital LLC (“Tower Arch”) and other interest holders in an all cash transaction valued at $620 million.

Future Infrastructure is a leading provider of non-discretionary maintenance, repair, upgrade and installation services to the telecommunication, regulated gas utility and infrastructure end markets. For the last 12 months ended September 30, 2020, FIH generated total revenue of $342 million, total adjusted earnings before income tax, depreciation and amortization (“adjusted EBITDA”) of $66 million and adjusted EBITDA margin of 19 percent.

Strategic Advantages and Benefits

  • Establishes a robust platform in the large and growing Telecommunication Services market; which is benefitting from multi-year tailwinds due to significant fiber deployments to support last-mile broadband capacity, the Internet of Things (“IoT”), 5G technology, and substantial growth in data consumption;
  • Complements and further strengthens Primoris’ existing utility services capabilities while introducing a number of potential cross-selling opportunities; and
  • Accelerates Primoris’ ongoing portfolio transition towards higher growth, higher margin, and recurring revenue under Master Service Agreements (“MSA”).

Financial Advantages and Benefits

  • The transaction is expected to be accretive to earnings in the first year and to enhance pro forma top line growth, gross margin and EBITDA and free cash flow generation;
  • Primoris anticipates significant tax benefits arising from the transaction with an expected net present value of at least $80 million;
  • Within 24 – 30 months after the close of the transaction, Primoris expects annual cost savings of at least $10 million from initiatives focused on: financial and IT systems, insurance programs savings and equipment spend optimization, among other factors.
  • Pro forma for the transaction Primoris net leverage remains comfortably below 3.0x net debt to adjusted EBITDA for the last 12 months ended September 30, 2020.

Tom McCormick, President and Chief Executive Officer of Primoris, said, “This acquisition is fully aligned with our strategic and operational goals and represents a defining moment for Primoris. It moves us meaningfully into a market we have been targeting and does so in a way that establishes a new, robust platform while creating additional opportunities for our existing services.”

“Our employees are our greatest assets and we just added approximately 1,100 very valuable assets to Primoris. We want to welcome the Future Infrastructure employees to the Primoris family of companies and look forward to working with all of them to grow this Company into what we all believe it can be,” added McCormick. “Our visions and cultures are aligned. Both organizations are passionate about safety and dedicated to quality. Additionally, we look forward to working with Future Infrastructure’s customers and suppliers and building on the positive relationships that have been created over the years.”

Curt Dowd, Chief Executive Officer of Future Infrastructure, commented, “I cannot imagine a better home for Future Infrastructure. Similar to Primoris, Future Infrastructure has developed an industry-leading reputation built on superior quality, reliability and a commitment to safety.”

Don Riggs, Founder and Chief Operating Officer of Future Infrastructure, added, “Future brings to Primoris a well-established brand and a comprehensive suite of operational capabilities serving a large base of blue-chip customers in a growing market. We are pleased to become a Primoris company.”

Upon completion of the transaction, Primoris expects Future Infrastructure’s platform of Telecom and Utility end markets businesses to be integrated into Primoris’ Utilities and Distribution Segment and Primoris’ Transmission and Distribution Segment, furthering Primoris’ strategic plan for service line expansion, new market entry and growth in the Company’s MSA revenue base.


Transaction Approvals and Closing Conditions


The transaction has been unanimously approved by the Boards of Directors of both Primoris and Future Infrastructure and is expected to close in the first quarter of 2021, depending on the timing of regulatory approvals.


Financing


The acquisition will be funded using $120 million of cash on hand, a revolving advance of $100 million under our existing credit facilities and proceeds from a new $400 million term loan. CIBC and Bank of the West are serving as Joint Lead Arrangers for Primoris on the financing.


Advisors


Goldman Sachs & Co. LLC is serving as lead financial advisor to Primoris. UBS Investment Bank is also providing financial advice. Gibson, Dunn & Crutcher LLP is serving as the Company’s legal counsel. BofA Securities is serving as exclusive financial advisor to Future Infrastructure. Kirkland & Ellis LLP is serving as Future Infrastructure’s legal counsel.


Conference Call


Tom McCormick, President and Chief Executive Officer, and Ken Dodgen, Executive Vice President and Chief Financial Officer, will host a conference call Tuesday, December 15, 2020 at 7:30 am Central Time / 8:30 am Eastern Time to discuss the transaction.

Interested parties may participate in the call by dialing:

  • (833) 476-0954 (Domestic)
  • (236) 714-2611 (International)

Presentation slides to accompany the conference call are available for download in the Investor Relations section of Primoris’ website at www.prim.com. Once at the Investor Relations section, please click on “Events & Presentations”.

If you are unable to participate in the live call, a replay may be accessed by dialing (800) 585-8367, conference ID 2192956, and will be available for approximately two weeks. The conference call will also be broadcast live over the Internet and can be accessed and replayed through the Investor Relations section of Primoris’ website at www.prim.com.
  
About Primoris Services Corporation
Founded in 1960, Primoris, through various subsidiaries, has grown to become one of the leading providers of specialty contracting services operating mainly in the United States and Canada. Primoris provides a wide range of specialty construction services, fabrication, maintenance, replacement, and engineering services to a diversified base of customers. The Company’s national footprint extends from Florida, along the Gulf Coast, through California, into the Pacific Northwest and into Canada. Additional information on Primoris is available at www.prim.com.

About Future Infrastructure

Future Infrastructure, founded in 1999, is a provider of maintenance, repair, upgrade, and installation services to the telecommunications, regulated utility gas, pipeline, transportation, and civil infrastructure customers throughout the southern and western regions of the United States. Additional information on Future Infrastructure is available at www.future-infrastructure.com.

About Tower Arch

Headquartered in Salt Lake City, UT, Tower Arch Capital is a lower-middle market private equity fund. Tower Arch focuses on partnering with and growing high-quality family and entrepreneur-owned companies to deliver long-term value for their management teams and investors. Tower Arch brings operational, consulting, and financial expertise to small companies to give them the tools they need to achieve their full potential. Target investments include control positions in entrepreneur and family-owned businesses with revenue between $20 million and $150 million or EBITDA between $5 million and $25 million. Additional information on Tower Arch Capital is available at www.towerarch.com.

FORWARD LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of the federal securities laws. These statements give the current expectations of the Company’s management. Words such as “could,” “will,” “may,” “assume,” “forecast,” “strategy,” “guidance,” “outlook,” “target,” “expect,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” or “project” and similar expressions are used to identify forward-looking statements. Without limiting the generality of the foregoing, forward-looking statements contained in this release include the Company’s expectations regarding the consummation of the transactions described herein.

Forward-looking statements can be affected by assumptions used or known or unknown risks or uncertainties. Consequently, no forward-looking statements can be guaranteed and actual results may differ materially and adversely from those reflected in the forward-looking statements. Factors that could cause actual results to differ materially from those indicated in the forward-looking statements include, among other things, (a) the risks and uncertainties disclosed in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and from time to time in our other filings with the Securities and Exchange Commission (“SEC”) and (b) the following risks inherent in the transactions (in addition to others described elsewhere in this document and in the subsequent filings with the SEC): failure to obtain regulatory approval necessary to consummate the transactions or to obtain regulatory approvals on favorable terms; failure to secure financing arrangements on favorable terms to consummate the transactions;  delays in consummating the transactions or the failure to consummate the transactions; the possibility of business disruption during the pendency of or following the transactions; the risk that management time may be diverted on transaction-related issues; the reaction of customers and other third parties to the proposed transactions; and other events or circumstances that could adversely impact the completion of the transactions, including the ongoing COVID-19 pandemic and other industry, political, competitive or economic conditions outside of our control.

Forward-looking statements speak only as of the date made and can be affected by assumptions the Company might make or by known or unknown risk and uncertainties. Many factors mentioned in this release and in the Company’s annual and quarterly reports will be important in determining future results. Consequently, you are urged to consider the limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of forward-looking statements, as the Company cannot assure you that the Company’s expectations or forecasts expressed in such forward-looking statements will be achieved. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For additional information, contact:

Brook Wootton
Vice President, Investor Relations
Primoris Services Corporation, 214-545-6773
[email protected]



Archrock Announces Upsizing and Pricing of $300 Million of Senior Notes

HOUSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) — Archrock, Inc. (NYSE: AROC) (“Archrock”) today announced the pricing of an upsized private offering by Archrock Partners, L.P. (“Archrock Partners”), a wholly-owned subsidiary of Archrock, of $300 million aggregate principal amount of 6.250% senior notes due 2028 (the “New Notes”) at an issue price of 104.875% of their face value. The size of the offering was increased by $50 million from the previously announced offering size of $250 million. The New Notes are being offered as additional notes under an indenture, dated December 20, 2019 (the “Indenture”), pursuant to which the Issuers previously issued $500 million aggregate principal amount of 6.250% senior notes due 2028 (the “Initial Notes”). The offering is expected to close on December 17, 2020, subject to the satisfaction of customary closing conditions. Archrock Partners Finance Corp., a wholly-owned subsidiary of Archrock Partners, will serve as co-issuer of the New Notes. The New Notes will have identical terms as the Initial Notes, other than the issue date, and the New Notes and the Initial Notes will be treated as a single class of securities under the Indenture. Archrock Partners intends to use the net proceeds of the sale of the New Notes to partially repay outstanding borrowings under its revolving credit facility and for general partnership purposes.

The New Notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and the rules promulgated thereunder and applicable state securities laws. The New Notes will be offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act and non-U.S. persons in transactions outside the United States in reliance on Regulation S under the Securities Act.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Archrock

Archrock is an energy infrastructure company with a pure-play focus on midstream natural gas compression. Archrock is the leading provider of natural gas compression services to customers in the oil and natural gas industry throughout the United States and a leading supplier of aftermarket services to customers that own compression equipment in the United States.

About Archrock Partners

Archrock Partners is a leading provider of natural gas compression services to customers in the oil and natural gas industry throughout the United States. Archrock owns all of the limited and general partnership interests in Archrock Partners.

Forward-Looking Statements

All statements in this release (and oral statements made regarding the subjects of this release) other than historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and factors that could cause actual results to differ materially from such statements, many of which are outside Archrock or Archrock Partners’ control. Forward-looking information includes, but is not limited to: statements regarding Archrock Partners’ proposed offering, the completion of such offering, the intended use of net proceeds from the proposed offering, and the impact of market conditions on such offering.

While Archrock and Archrock Partners believe that the assumptions concerning future events are reasonable, they caution that there are inherent difficulties in predicting certain important factors that could impact the future performance or results of its business. Among the factors that could cause results to differ materially from those indicated by such forward-looking statements are: local, regional and national economic conditions and the impact they may have on Archrock Partners’ and its customers; conditions in the oil and gas industry, including the level of production of, demand for or price of oil or natural gas; changes in safety, health, environmental and other regulations; the financial condition of Archrock Partners’ customers; the failure of any customer to perform its contractual obligations; and the performance of Archrock.

These forward-looking statements are also affected by the risk factors, forward-looking statements and challenges and uncertainties described in Archrock’s Annual Report on Form 10-K for the year ended December 31, 2019, and those reports set forth from time to time in Archrock’s filings with the Securities and Exchange Commission, which are available at www.archrock.com. Except as required by law, Archrock and Archrock Partners expressly disclaim any intention or obligation to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

SOURCE: Archrock, Inc.


For information, contact:

Megan Repine
Vice President, Investor Relations
(281) 836-8360
[email protected]



GAMCO Investors Files Trademark Application For New ETF

GAMCO Investors Files Trademark Application For New ETF

GREENWICH, Conn.–(BUSINESS WIRE)–
GAMCO Investors, Inc. (“GAMCO”) (NYSE: GBL) has filed a trademark application for Gabelli Love Our Planet & People ETFTM, which is its first ETF in a trust of nine Precidian ActiveShares actively managed ETFs.

Gabelli Love Our Planet & People ETF is an Environmental, Social, and Governance (ESG) ETF that will emphasize the environmental aspect, or “E” in ESG, placing an emphasis on investing in publicly traded companies with a focus on sustainability. The Fund combines a research intensive process with social screens and a holistic ESG overlay to deliver returns in a socially responsive manner. The launch of the ETF is pending Securities and Exchange Commission approval of a final registration statement.

GAMCO Investors, Inc. (NYSE:GBL), through its subsidiaries, manages assets of private advisory accounts (GAMCO) and mutual funds and closed-end funds (Gabelli Funds, LLC), and is known for its Private Market Value with a Catalyst™ style of investment. As of September 30, 2020, GAMCO Investors, Inc. had $29.7 billion in assets under management. Further information can be found at www.gabelli.com.

About Gabelli Love Our Planet & People ETF

Gabelli Love Our Planet & People ETF is a diversified, open-end management investment company whose primary investment objective is to seek capital appreciation. Under normal market conditions, the Fund will invest at least 80%, of its assets in U.S. exchange-listed common and preferred stocks of companies that meet the Fund’s guidelines for environmental responsibility at the time of investment. Your investment in the Fund is not guaranteed and you could lose some or all of the amount you invested. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (NYSE:GBL).

These ETFs are not yet available to purchase, and this is not a solicitation to purchase a security. Please read the Prospectus, including the Risk Discussion, carefully (when it becomes available) to understand the attributes and risks of these ETF before investing.

This ETF is different from traditional ETFs. Traditional ETFs tell the public what assets they hold each day. This ETF will not. This may create additional risks for your investment. For example:

  • You may have to pay more money to trade the ETF’s shares. This ETF will provide less information to traders, who tend to charge more for trades when they have less information.
  • The price you pay to buy ETF shares on an exchange may not match the value of the ETF’s portfolio. The same is true when you sell shares. These price differences may be greater for this ETF compared to other ETFs because it provides less information to traders.
  • These additional risks may be even greater in bad or uncertain market conditions. The differences between this ETF and other ETFs may also have advantages. By keeping certain information about the ETF secret, this ETF may face less risk that other traders can predict or copy its investment strategy. This may improve the ETF’s performance. If other traders are able to copy or predict the ETF’s investment strategy, however, this may hurt the ETF’s performance. For additional information regarding the unique attributes and risks of the ETF, see the ActiveShares prospectus/registration statement.

You should consider the ETFs’ investment objectives, risks, charges and expenses carefully before you invest. The ETFs’ Prospectus, which will be available from G.distributors, LLC, a registered broker-dealer and FINRA member firm, will contain this and other information about the ETFs, and should be read carefully before investing.

Gabelli Funds, LLC is a registered investment adviser with the Securities and Exchange Commission and is a wholly owned subsidiary of GAMCO Investors, Inc.

To obtain a Prospectus (when it becomes available), please call 800-GABELLI or visit https://www.gabelli.com/funds/etfs/intro.

John Ball

Senior Vice President

(914) 921-7728

For further information please visit www.gabelli.com.

KEYWORDS: New York Connecticut United States North America

INDUSTRY KEYWORDS: Finance Banking Environment Professional Services Other Professional Services

MEDIA:

Mesoblast Corporate Update

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update.

The webcast will begin at 9.00am AEDT, Tuesday, December 15; 5.00pm EST, Monday, December 14, 2020. It can be accessed via https://webcast.boardroom.media/mesoblast-limited/20201214/NaN5fd6e483de11ae0019f60917

The archived webcast will be available on the Investor page of the Company’s website:
www.mesoblast.com

About Mesoblast

Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2040 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Mesoblast has completed Phase 3 trials of rexelemestrocel-L for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking Statements

This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions and variations thereof. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. The risks, uncertainties and other factors that may impact our forward-looking statements include, but are not limited to: the timing, progress and results of Mesoblast’s preclinical and clinical studies; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblast’s product candidates, if approved; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. Unless required by law, we do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive

For more information, please contact:


Corporate Communications / Investors
                                    
Schond Greenway
T: +1 212 880 2060
E: [email protected]
  Paul Hughes
T: +61 3 9639 6036
E: [email protected]
     

Media


Kristen Bothwell
T: +1 917 613 5434
E: [email protected]